Spectrum Health authorized to administer monoclonal antibodies to non-hospitalized COVID-19 patients
The U.S. Food and Drug Administration is giving Spectrum Health Emergency Use Authorization for two monoclonal antibodies for treating non-hospitalized patients with mild to moderate COVID-19 symptoms.
The two monoclonal antibodies infusion treatments are from pharmaceutical companies Eli Lilly and Regeneron and are being offered at a new infusion clinic at East Grand Rapids' Blodgett Hospital. The intravenous treatment takes one hours. From start to finish, patients will require a three hour stay.
The monoclonal antibodies treatments have shown few side effects and can help to prevent patients from developing severe COVID-19 symptoms.